PTCT

PTC Therapeutics, Inc. [PTCT] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

PTCT Stock Summary

Top 10 Correlated ETFs

PTCT


Top 10 Correlated Stocks

PTCT


In the News

03:01 29 Mar 2024 PTCT

PTC Therapeutics (PTCT) Up on Positive Regulatory Updates

PTC Therapeutics (PTCT) submits BLA for gene therapy Upstaza to the FDA and announces plans to resubmit its application for Translarna to the regulatory body. Its shares rise on these updates.

10:48 29 Mar 2024 PTCT

PTC Therapeutics, Inc. (PTCT) Q4 2023 Earnings Call Transcript

PTC Therapeutics, Inc. (PTCT) Q4 2023 Earnings Call Transcript

07:01 29 Mar 2024 PTCT

Here's What Key Metrics Tell Us About PTC Therapeutics (PTCT) Q4 Earnings

While the top- and bottom-line numbers for PTC Therapeutics (PTCT) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

06:21 29 Mar 2024 PTCT

PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates

PTC Therapeutics (PTCT) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of $0.29. This compares to loss of $2.35 per share a year ago.

05:20 29 Mar 2024 PTCT

PTC Therapeutics to Participate at Upcoming Investor Conferences

SOUTH PLAINFIELD, N.J. , Feb. 27, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: TD Cowen 44th Annual Health Care Conference Monday, March 4, at 1:30 p.m.

04:23 29 Mar 2024 PTCT

PTC Therapeutics' muscle disorder drug fails to secure EU regulator backing

The European health regulator's advisory panel issued a negative opinion for PTC Therapeutics' drug to treat Duchenne muscular dystrophy (DMD), an inherited progressive muscle-wasting disorder, the company said on Thursday.

06:11 29 Mar 2024 PTCT

PTC Therapeutics, Inc. (PTCT) Q3 2023 Earnings Call Transcript

PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q3 2023 Earnings Conference Call February 8, 2023 9:00 AM ET Company Participants Jane Hanlon - Associate Director, Investor Relations Matthew Klein - Chief Executive Officer Eric Pauwels - Chief Business Officer Kylie O'Keefe - Chief Commercial Officer Pierre Gravier - Chief Financial Officer Conference Call Participants Eric Joseph - J.P. Morgan Kristen Kluska - Cantor Fitzgerald Samantha Corwin - William Blair David Lebowitz - Citi Brian Abrahams - RBC Capital Markets Colin Bristow - UBS Jeff Hung - Morgan Stanley Alexander Xenakis - Truist Securities Joseph Schwartz - Leerink Partners Gena Wang - Barclays Paul Choi - Goldman Sachs Tazeen Ahmad - Bank of America Operator Thank you for standing by and welcome to the PTC Therapeutics Third Quarter 2023 Financial Results Conference Call.

08:33 29 Mar 2024 PTCT

Why Is PTC Therapeutics (PTCT) Stock Down 23% Today?

PTC Therapeutics (NASDAQ: PTCT ) stock is falling on Friday after the biopharmaceutical company released its earnings report for the third quarter of 2023. The bad news for PTCT stock starts with its earnings per share of -$1.76.

09:03 29 Mar 2024 PTCT

PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

06:48 29 Mar 2024 PTCT

PTC Therapeutics (PTCT) Reports Q3 Loss, Lags Revenue Estimates

PTC Therapeutics (PTCT) came out with a quarterly loss of $1.76 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $1.53 per share a year ago.

PTCT Financial details

Company Rating
Sell
Market Cap
2.23B
Income
-626.6M
Revenue
937.82M
Book val./share
-10.84
Cash/share
11.61
Dividend
-
Dividend %
-
Employees
988
Optionable
Yes
Shortable
Yes
Earnings
25 Apr 2024
P/E
-3.37
Forward P/E
-5.88
PEG
-4.61
P/S
2.71
P/B
-3.23
P/C
2.51
P/FCF
-6.31
Quick Ratio
0.94
Current Ratio
1.1
Debt / Equity
-0.37
LT Debt / Equity
-0.35
-
-
EPS (TTM)
-8.36
EPS next Y
-4.95
EPS next Q
-1.61
EPS this Y
7.45%
EPS next Y
-40.81%
EPS next 5Y
-91.89%
EPS last 5Y
14.41%
Revenue last 5Y
25.03%
Revenue Q/Q
56.2%
EPS Q/Q
17.05%
-
-
-
-
SMA20
-
SMA50
3.57%
SMA100
45%
Inst Own
74.56%
Inst Trans
0.68%
ROA
-51%
ROE
125%
ROC
-0.79%
Gross Margin
94%
Oper. Margin
-76%
Profit Margin
-80%
Payout
-
Shs Outstand
76.61M
Shs Float
73.66M
-
-
-
-
Target Price
47.25
52W Range
17.53-59.84
52W High
-50.69%
52W Low
+71.12%
RSI
52
Rel Volume
0.79
Avg Volume
1.03M
Volume
807.28K
Perf Week
-3.58%
Perf Month
12.27%
Perf Quarter
36.25%
Perf Half Y
28.72%
-
-
-
-
Beta
0.665
-
-
Volatility
0.43%, 1.63%
Prev Close
0%
Price
29.09
Change
-1.32%

PTCT Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
5.225.777.649.7412.53
Net income per share
-4.27-6.64-7.43-7.79-8.37
Operating cash flow per share
-1.68-2.94-3.57-4.97-2.12
Free cash flow per share
-2.45-3.79-4.78-7.1-3.73
Cash per share
18.4316.7119.267.5511.72
Book value per share
10.17.30.02-4.84-10.94
Tangible book value per share
-3.37-4.78-11.43-15.83-17.11
Share holders equity per share
10.17.30.02-4.84-10.94
Interest debt per share
5.127.229.6111.085.74
Market cap
2.83B4.03B2.81B2.74B2.06B
Enterprise value
2.45B4.24B2.46B3.03B1.88B
P/E ratio
-11.24-9.2-5.36-4.9-3.29
Price to sales ratio
9.2110.585.213.922.2
POCF ratio
-28.66-20.76-11.17-7.68-13.02
PFCF ratio
-19.62-16.12-8.34-5.38-7.39
P/B Ratio
4.768.361.95K-7.89-2.52
PTB ratio
4.768.361.95K-7.89-2.52
EV to sales
811.144.584.342.01
Enterprise value over EBITDA
-21.02-18.62-6.52-8.13-16.7
EV to operating cash flow
-24.88-21.85-9.81-8.5-11.89
EV to free cash flow
-17.04-16.96-7.32-5.95-6.75
Earnings yield
-0.09-0.11-0.19-0.2-0.3
Free cash flow yield
-0.05-0.06-0.12-0.19-0.14
Debt to equity
0.530.87411.16-2.03-0.37
Debt to assets
0.190.190.310.410.16
Net debt to EBITDA
3.19-0.930.9-0.791.59
Current ratio
3.34.441.521.712.02
Interest coverage
15.43-7.06-4.36-4.84-2.7
Income quality
0.390.440.480.640.25
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
0.841.2510.930.71
Intangibles to total assets
0.490.360.420.460.24
Capex to operating cash flow
0.460.290.340.430.76
Capex to revenue
-0.15-0.15-0.16-0.22-0.13
Capex to depreciation
-1.41-0.66-1.33-1.18-0.51
Stock based compensation to revenue
0.140.180.190.160.14
Graham number
31.1633.011.8529.1345.39
ROIC
-0.22-0.43-0.54-0.860.78
Return on tangible assets
-0.3-0.31-0.46-0.61-0.43
Graham Net
1.82-8.49-6.94-19.29-22.84
Working capital
543.43M954.41M264.03M287.55M615.53M
Tangible asset value
-198.51M-315.69M-805.74M-1.14B-1.28B
Net current asset value
-250.17M-494.55M-1.16B-1.36B-1.5B
Invested capital
0.530.87411.16-2.03-0.37
Average receivables
61.72M62.73M90.19M133.03M158.32M
Average payables
8.16M14.49M20.85M25.15M16.66M
Average inventory
17.7M18.99M17.28M18.83M26.19M
Days sales outstanding
66.0367.0374.8581.2862.67
Days payables outstanding
310.53359.66260.05222.777.66
Days of inventory on hand
580.06360.28179.02178.1638.74
Receivables turnover
5.535.454.884.495.82
Payables turnover
1.181.011.41.6447.66
Inventory turnover
0.631.012.042.059.42
ROE
-0.42-0.91-364.331.610.77
Capex per share
-0.77-0.85-1.21-2.13-1.61

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
2.312.992.862.614.07
Net income per share
-2.36-1.88-2.66-1.76-2.06
Operating cash flow per share
-2.29-0.4-0.19-0.19-1.33
Free cash flow per share
-2.66-0.99-0.45-0.58-1.71
Cash per share
7.473.884.523.9111.61
Book value per share
-4.79-6.21-7.75-8.9-10.84
Tangible book value per share
-15.66-16.63-14.9-15.61-16.96
Share holders equity per share
-4.79-6.21-7.75-8.9-10.84
Interest debt per share
10.049.889.88.974.56
Market cap
2.77B3.57B3.04B1.69B2.08B
Enterprise value
3.06B4.11B3.53B2.23B1.9B
P/E ratio
-4.05-6.43-3.82-3.18-3.34
Price to sales ratio
16.5316.2114.228.596.78
POCF ratio
-16.68-121.1-215.25-116.35-20.75
PFCF ratio
-14.34-48.82-90.99-38.63-16.16
P/B Ratio
-7.97-7.81-5.25-2.52-2.54
PTB ratio
-7.97-7.81-5.25-2.52-2.54
EV to sales
18.2818.6316.5311.346.19
Enterprise value over EBITDA
-34.1-62.35-51.84-18.8622.69
EV to operating cash flow
-18.44-139.2-250.25-153.48-18.97
EV to free cash flow
-15.86-56.11-105.78-50.96-14.77
Earnings yield
-0.06-0.04-0.07-0.08-0.07
Free cash flow yield
-0.07-0.02-0.01-0.03-0.06
Debt to equity
-2.03-1.53-1.21-1.05-0.37
Debt to assets
0.410.440.530.560.16
Net debt to EBITDA
-3.26-8.11-7.25-4.56-2.14
Current ratio
1.711.391.241.12.02
Interest coverage
-6.56-4.22-7.124.20.07
Income quality
0.970.210.070.110.64
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0000.410.26
Research and developement to revenue
1.130.890.870.840.4
Intangibles to total assets
0.460.480.40.40.24
Capex to operating cash flow
0.161.481.372.010.28
Capex to revenue
-0.16-0.2-0.09-0.15-0.09
Capex to depreciation
-0.69-1.02-0.38-0.47-0.35
Stock based compensation to revenue
0.160.130.140.290.05
Graham number
15.9316.2221.5418.7922.43
ROIC
-0.3-0.32-0.69-0.57-0.01
Return on tangible assets
-0.19-0.17-0.25-0.18-0.11
Graham Net
-19.08-21.91-19.14-19.82-22.63
Working capital
287.55M171.76M113.35M48.24M615.53M
Tangible asset value
-1.14B-1.23B-1.11B-1.18B-1.28B
Net current asset value
-1.36B-1.45B-1.33B-1.39B-1.5B
Invested capital
-2.03-1.53-1.21-1.05-0.37
Average receivables
140.04M178.74M189.69M171.61M163.37M
Average payables
24.07M26.79M26.03M22.45M12.6M
Average inventory
18.31M24.23M29.33M33.89M33.16M
Days sales outstanding
83.6682.4474.7275.8747.2
Days payables outstanding
225.29167.42181.97181.575.12
Days of inventory on hand
180.18169.57226.35338.9525.89
Receivables turnover
1.081.091.21.191.91
Payables turnover
0.40.540.490.517.58
Inventory turnover
0.50.530.40.273.48
ROE
0.490.30.340.20.19
Capex per share
-0.37-0.59-0.26-0.39-0.38

PTCT Frequently Asked Questions

What is PTC Therapeutics, Inc. stock symbol ?

PTC Therapeutics, Inc. is a US stock , located in South plainfield of Nj and trading under the symbol PTCT

Is PTC Therapeutics, Inc. buy or a sell ?

4 stock analysts have 4 predictions with a medium analyst target price of $47.25. The lowest prediction is $35 and the highest is $63

What is PTCT stock prediction ?

What is PTC Therapeutics, Inc. stock quote today ?

PTC Therapeutics, Inc. stock price is $29.09 today.

Is PTC Therapeutics, Inc. stock public?

Yes, PTC Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap